Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
- PMID: 37803437
- PMCID: PMC10557237
- DOI: 10.1186/s12885-023-11366-4
Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
Abstract
Objectives: Pan-immune-inflammation value (PIV) is defined by the neutrophil, platelet, monocyte, and lymphocyte counts and is associated with immune-checkpoint inhibitor (ICI) therapy outcomes in advanced non-small cell lung cancer (aNSCLC). However, PIV is dynamic under therapy and its longitudinal assessment may help predict efficacy. This study investigated the impact of baseline PIV and its dynamics on ICI efficacy and its immune-related adverse events (irAEs). The study additionally attempted to understand the biological significance of PIV.
Patients and methods: This retrospective study analyzed the clinical data of 269 consecutive patients with aNSCLC. PIV was calculated at baseline and at weeks 3-4 to determine its association with overall survival (OS), progression-free survival (PFS), and irAEs.
Results: Results revealed that low baseline PIV was positively correlated with the incidence of irAEs. Moreover, a low PIV at baseline was significantly associated with a prolonged PFS (median PFS: 10 vs. 7 months, p = 0.0005) and OS (median OS: 29 vs. 21 months, p < 0.0001). When the PIV at baseline and weeks 3-4 was considered together, its low dynamics correlated with a higher incidence of irAEs (p = 0.001), a longer PFS (median PFS, 9 vs. 6 months, p = 0.012), and a longer OS (median OS; 28 vs. 21 months, p = 0.002).
Conclusion: Thus, PIV at baseline and its dynamics are novel and potent predictors of irAEs, PFS, and OS in patients with aNSCLC receiving immunotherapy. Moreover, the PIV dynamics may be an effective, novel surrogate marker to dynamically observe the efficacy of immunotherapy.
Keywords: Blood biomarkers; Dynamics; Immune-checkpoint inhibitors; Immune-related adverse events; Non-small-cell lung cancer; Pan-immune-inflammation value.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11. Clin Lung Cancer. 2019. PMID: 30442524
-
Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be Regarding Our Treatment Decisions?Medicina (Kaunas). 2024 Nov 1;60(11):1792. doi: 10.3390/medicina60111792. Medicina (Kaunas). 2024. PMID: 39596977 Free PMC article.
-
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21. Clin Lung Cancer. 2019. PMID: 30885550
-
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Immunotherapy. 2023 Feb;15(3):209-220. doi: 10.2217/imt-2022-0028. Epub 2023 Jan 30. Immunotherapy. 2023. PMID: 36710655
-
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.Cancer Treat Rev. 2021 Jan;92:102134. doi: 10.1016/j.ctrv.2020.102134. Epub 2020 Dec 3. Cancer Treat Rev. 2021. PMID: 33302134
Cited by
-
Association between pan-immune-inflammation value and dyslipidemia in the United States population.Front Endocrinol (Lausanne). 2025 Mar 17;16:1518304. doi: 10.3389/fendo.2025.1518304. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40166678 Free PMC article.
-
Association of pan-immune inflammation value with mortality in patients with pulmonary embolism: a cohort study.Sci Rep. 2025 Feb 24;15(1):6571. doi: 10.1038/s41598-025-90951-y. Sci Rep. 2025. PMID: 39994429 Free PMC article.
-
Pan-immune-inflammation value in lung cancer: prognostic significance and implications for therapeutic guidance - a systematic review and meta-analysis.World J Surg Oncol. 2025 Jun 23;23(1):250. doi: 10.1186/s12957-025-03910-2. World J Surg Oncol. 2025. PMID: 40551126 Free PMC article.
-
Inflammatory and Metabolic Predictors of Mortality in Pulmonary Thromboembolism: A Focus on the Triglyceride-Glucose Index and Pan-Immune Inflammation Value.J Clin Med. 2024 Oct 9;13(19):6008. doi: 10.3390/jcm13196008. J Clin Med. 2024. PMID: 39408068 Free PMC article.
-
Prognostic Value of Blood-Based Inflammatory Markers in Cancer Patients Receiving Immune Checkpoint Inhibitors.Cancers (Basel). 2024 Dec 26;17(1):37. doi: 10.3390/cancers17010037. Cancers (Basel). 2024. PMID: 39796668 Free PMC article.
References
-
- Parkin DM, Pisani P, Ferlay J. Global cancer statistics. Ca-cancer j clin. 1999;49(1):33–64. - PubMed
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Ca-cancer j clin. 2021;71(3):209–49. - PubMed
-
- Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, diagnosis, and treatment. Mayo clin proc. 2019;94(8):1623–40. - PubMed
-
- Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, Bueno TM, Bernabé-Caro R, Parente DP, Ruiz-Gracia P, et al. PD-(L)1 inhibitors as Monotherapy for the First-Line treatment of Non-Small-Cell Lung Cancer patients with high PD-L1 expression: a Network Meta-Analysis. J Clin Med. 2021;10(7):null. - PMC - PubMed
MeSH terms
Substances
Grants and funding
- 82273955, 82204504/National Natural Science Foundation of China
- 82273955, 82204504/National Natural Science Foundation of China
- 82273955, 82204504/National Natural Science Foundation of China
- M2022080/Scientific research project of Jiangsu Provincial Health Commission
- M2022080/Scientific research project of Jiangsu Provincial Health Commission
- M2022080/Scientific research project of Jiangsu Provincial Health Commission
- MS22021025, MS22022025/Science and Technology Project of Nantong City
- MS22021025, MS22022025/Science and Technology Project of Nantong City
- MS22021025, MS22022025/Science and Technology Project of Nantong City
- LCYJ-A10/Multicenter Study Project of Affiliated Hospital of Nantong University
- LCYJ-A10/Multicenter Study Project of Affiliated Hospital of Nantong University
- LCYJ-A10/Multicenter Study Project of Affiliated Hospital of Nantong University
LinkOut - more resources
Full Text Sources
Medical